semaglutide raise heart rate GLP-1 Agonists and Semaglutide cardiovascular outcomes align more
Description
These adaptations position irisin as a promising therapeutic target for preventing metabolic disorders and optimizing exercise protocols
Participants received diet (500kcaldeficit per day) and exercise counseling during 2-week run-in, before being randomly assigned (with a telephone or web-based system) to once-daily subcutaneous liraglutide (1.2, 1.8, 2.4 or 3.0mg, n=9095), placebo (n=98) or open-label orlistat (120mg 3, n=95)
Registration: URL: Unique identifier: NCT01720446 and NCT02692716
Health & Wellness, Lifestyle
* DPP4 8 (Aib)
